The catalytic performance of the chiral phase-transfer catalyst 1 (0.1–0.01 mol %) in the asymmetric alkylation of protected glycine and alanine derivatives exceeds that of existing catalysts. The reaction is used in the enantioselective synthesis of structurally diverse natural and non-natural α-alkyl and α,α-dialkyl-α-amino acids.
No takes yet. Share an insight, caveat, or question.
Kitamura et al. (2005) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: